NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Zevra Therapeutics, Inc. ZVRA
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$106.5M
▲ 350.9% vs FY2024
EPS · FY25
$1.35
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
85.7%
Net margin · FY25
78.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 106.5M
Revenue, FY2025 · full 13-year series below
Revenue
Net income
78 cents of every revenue dollar became profit this year.
Per share
USD 1.35
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
85.7%
Return on equity, FY2025
ROE
Operating margin-59.1%
Net margin78.2%
Return on assets36.0%
Each USD of equity produced 86 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+51.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+118.8%
+51.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 284.7M
total assets, end of FY2025
Total assetsUSD 284.7M
EquityUSD 154.7M
CashUSD 62.4M
Gross debtUSD 61.9M
Net debtUSD -478,000.00
Current ratio5.68×
The company holds more cash than debt.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.0
−0.0
0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.0
−0.0
0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
Net income $B
0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.1
−0.0
−0.0
EPS, diluted $
1.35
−2.28
·
·
−2.11
−3.21
−13.23
−3.15
−2.96
−1.13
−7.42
−10.27
−2.20
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
85.7
−207.8
−67.2
−30.3
−48.5
·
·
·
·
·
·
·
·
Shares out B
0.06
0.05
0.04
0.03
0.04
0.00
0.00
0.00
0.01
0.01
0.01
0.00
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
37 of 37
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed